Abstract | AIM: The aim of this study was to evaluate the use of Patent Blue V for identification of the sentinel node in patients with colon carcinoma. METHOD: From May 2002, 35 patients operated for colon carcinoma underwent lymphatic mapping using Patent Blue V as marker. Either directly after resection of the colon or during operation 2 ml of Patent Blue V was injected peritumourally, and the first 1 to 4 blue nodes were marked as sentinel nodes. Pathological evaluation was done on a single HE-stained section of all lymph nodes. Only if all sentinel nodes were negative for metastases, serial sectioning and additional immunohistochemical staining against keratine CK 7/8 was performed to reveal micrometastasis in the sentinel nodes. RESULTS: In 33/35 of patients at least one sentinel node was identified. In 10/33 the sentinel node was positive for metastases, and in 5/10 this was the only node containing metastases. One patient had a false negative sentinel node (accuracy 97%, sensitivity 91%). CONCLUSION: Using Patent Blue V, it is possible to identify the sentinel node in most patients with colon cancer. The results are comparable with other sentinel node studies using Lymphazurin.
|
Authors | A E Braat, J W A Oosterhuis, F C P Moll, J E de Vries |
Journal | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
(Eur J Surg Oncol)
Vol. 30
Issue 6
Pg. 633-7
(Aug 2004)
ISSN: 0748-7983 [Print] England |
PMID | 15256237
(Publication Type: Journal Article)
|
Chemical References |
- Coloring Agents
- Rosaniline Dyes
- sulfan blue
|
Topics |
- Colectomy
(methods)
- Colonic Neoplasms
(pathology, surgery)
- Coloring Agents
- Humans
- Lymphatic Metastasis
- Neoplasm Staging
- Rosaniline Dyes
- Sentinel Lymph Node Biopsy
(methods)
- Treatment Outcome
|